||||
||||
|||
|
||||
|||
||

46th Annual Scientific Meeting

20/20 Vision
Embracing innovation that builds on past success

July 6 - 9, 2020 | Hyatt Regency Jacksonville-Riverfront | Jacksonville, Florida


FEATURED PROGRAMMING

Special Guest Lecture  | Marc Beer 
Co-Founder, Chairman & CEO of Renovia

A Primer on Medical Device Innovation – How to Avoid Common Pitfalls while Realizing Your Vision
Tuesday, July 7th | 2:20 pm to 3:00 pm

Marc brings more than 25 years of development and commercialization experience in biotechnology, pharmaceuticals, devices, and diagnostics. Marc founded Renovia with Ramon Iglesias, MD and Yolanda Lorié in August 2016 and successfully closed a Series A financing with leading healthcare venture capital funds.

Marc is the former Chief Executive Officer of Aegerion Pharmaceuticals, Inc. (NASDAQ: AEGR). Aegerion is a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for patients with debilitating rare diseases.  

Marc took the company public in October 2010. The Company’s first marketed product, JUXTAPID® (lomitapide) was approved by the US Food and Drug Administration in December 2012 for homozygous familial hypercholesterolemia. During his tenure, JUXTAPID obtained marketing approval in 36 countries. Additionally, Aegerion acquired its second product, MYALEPT® (metreleptin), approved in the US for generalized lipodystrophy, an ultra-rare disease.

In April 2000, Marc became the Founding CEO of ViaCell (NASDAQ: VIAC), a biotechnology company specializing in the collection, preservation, and development of umbilical cord blood stem cells, and over a period of seven years led the company from its inception to a rapidly growing and robust commercial organization. Under Marc’s leadership, the company grew to more than 300 employees, went public in 2005 and was ultimately acquired in 2007 by PerkinElmer (NYSE: PKI).

While serving as CEO of ViaCell, Marc also served as a member of the board of directors of Erytech Pharma (NASDAQ: ERYP), a publicly traded biopharmaceutical company. Prior to ViaCell, Marc held various positions within Genzyme, most recently as Vice President of Global Marketing where he was responsible for the commercial launch of several products addressing rare disease populations on a global scale.

Prior to Genzyme, he held a variety of sales and marketing roles in the pharmaceutical and diagnostic divisions of Abbott Laboratories (NYSE: ABT). He also was a former member of the Mass Life Science Board of the Commonwealth of Massachusetts and served on the Biotechnology Industry Organization (BIO) Emerging Companies Section Governing Board.